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Muscular dystrophies comprise a heterogeneous group of neuromuscular disorders, characterized by progressive muscle wasting, for which no
satisfactory treatment exists. Multiple stem cell populations, both of adult or embryonic origin, display myogenic potential and have been assayed
for their ability to correct the dystrophic phenotype. To date, many of these described methods have failed, underlying the need to identify the
mechanisms controlling myogenic potential, homing of donor populations to the musculature, and avoidance of the immune response. Recent
results focus on the fresh isolation of satellite cells and the use of multiple growth factors to promote mesangioblast migration, both of which
promote muscle regeneration. Throughout this chapter, various stem cell based therapies will be introduced and evaluated based on their potential
to treat muscular dystrophy in an effective and efficient manner.
© 2006 Elsevier B.V. All rights reserved.Keywords: Stem cell; Muscular dystrophy; Skeletal muscle; Regenerative medicine; Cell therapy1. Introduction
1.1. Muscular dystrophy
Numerous types of muscular dystrophy exist and differ
depending on their degree of severity and the muscle types
affected [1]. Duchenne muscular dystrophy (DMD), the most
common form of muscular dystrophy, is an X-linked genetic
disorder that occurs at a rate of approximately 1 in 3500 male
births [2]. DMD arises due to either spontaneous mutations or
inherited nonsense point mutations in the dystrophin gene [3,4],
the result of which is progressive muscle wasting and weakness
attributed to the loss of a functional dystrophin protein [5].
Dystrophin, an important cytoskeletal protein, and a major
component of the dystrophin–glycoprotein complex (DGC), is
responsible for the maintenance of cell integrity, mediation of
cytoplasmic signaling and muscle cell function [6]. Without
dystrophin, muscle cells cannot form the DGC and degenerate
as a result of mechanical stress during contraction.
To test prospective therapeutic treatments for DMD
numerous large and small animal models have been created;⁎ Corresponding author.
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defects seen in diaphragm muscle as a result of a genetic
mutation causing premature termination of the dystrophin
transcript [7,8]. Although the mdx mouse lacks a functional
dystrophin protein, it only displays a mild dystrophic pheno-
type, which is attributed to a greater degree of fiber regeneration
and a reduction in endomysial fibrosis compared to DMD [9].
More recent mouse models include the utrophin/dystrophin null
mouse [10,11] and the dystrophin/α7-integrin double mutant
mouse, both of which more closely resemble human DMD
[12,13]. Feline [14], zebrafish [15], and the canine X-linked
model of muscular dystrophy [16,17] complement the mouse
models and provide researchers with additional tools to study
this disease.
1.2. The function of stem cells in development and tissue
homeostasis
Stem cells are defined by certain characteristics, primarily an
ability for long term self renewal and the capacity to
differentiate into multiple cell lineages. Stem cells are
responsible for the development and maintenance of tissues
and organs and self-renew or differentiate in response to a
combination of biochemical signals and biomechanical stimuli
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either adult or embryonic tissue, and depending on a
hierarchical state differ in their ability to give rise to multiple
cell lineages. This hierarchy progresses from a state of
totipotency through to unipotency; whereby, at each level the
ability to differentiate into multiple cell types is progressively
diminished (Fig. 1). Stem cell division can be either symmetric
or asymmetric. An asymmetric division results in the formation
of two non-identical daughter cells; one commits to a
specialized fate while the other remains quiescent to maintain
the stem cell pool. Conversely, differentiating daughter cells
undergo symmetric divisions giving rise to a reservoir of
precursor cells that contribute to tissue regeneration.
Small quantities of adult stem cells exist in most tissues
throughout the body where they remain quiescent for long
periods of time prior to being activated in response to disease or
tissue injury. Adult stem cells can be isolated from cells of the
hematopoietic [18], neural [19], dermal [20], muscle [21–23]
and hepatic [24] systems. It is traditionally thought that adult
stem cells give rise to the specialized cell types of the tissue
from which they originated. However, some recent reports have
indicated that adult stem cells can differentiate into lineages
other then their tissue of origin, for example transplanted bone
marrow or enriched hematopoietic stem cells (HSCs) are
reported to give rise to cells of the mesoderm [25–30],
endoderm [31,32], and ectoderm [33,34]. Future experiments
elaborating upon the origins and characteristics of adult stem
cells are necessary in order to fully distinguish their potential
from embryonic stem cells.
The embryonic stem cell (ESC) is defined by its origin—the
inner cell mass of the blastocyst. ESCs traditionally differ from
adult stem cells in that they are deemed pluripotent; meaningFig. 1. Stem cell hierarchy. Progression of stem cells during development from a sta
types highlighting the divergence of cell lineages.they can give rise to cells derived from all three germ layers
[35]. Gene expression patterns observed during the in vitro
differentiation of ESCs mimic that seen in vivo; and these cells
can give rise to numerous cell types in vitro including neurons
[36], bone [37,38], pancreatic islets [39], and skeletal muscle
[40].
In the past multiple stem cell populations have been assayed
for their ability to treat muscular dystrophy, the majority of
which have met with limited success. In order to correct the
dystrophic phenotype, transplanted cells must fuse to existing,
or form new, myotubes. Upon fusion, the contribution of
genetically normal myonuclei to the muscle myofiber should
result in the production of a functional dystrophin protein. Stem
cell based therapies for the treatment of muscular dystrophy can
progress via two strategies. The first involves cells from a
patient afflicted with DMD and is termed autologous stem cell
transfer. In this process cells from the patient are genetically
altered in vitro to restore dystrophin expression and subse-
quently re-implanted (reviewed [41,42]). In the second strategy,
allogenic stem cell transfer, cells are isolated from an individual
with functional dystrophin and subsequently transplanted into a
dystrophic patient (reviewed [43]). Both of these strategies have
advantages and disadvantages. Autologous cells are advanta-
geous in that they are derived from the patient and therefore
unlikely to elicit an immune response. However, the process of
genetic alteration has in the past led to undesirable effects
including transformation of donor cells and even death [44–46].
Allogenic cells, on the other hand, are not subject to genetic
modification, making them ideal for functional muscle regene-
ration. However, the patient is at risk for immune rejection,
raising the issues of donor compatibility and appropriate immu-
nosuppressive regimes. In this chapter, multiple sources of stemte of totipotency through to terminal differentiation with intermediate stem cell
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candidacy as cell sources to treat muscular dystrophy will be
assessed. The identification of a stem cell population that
provides efficient and effective muscle regeneration is critical
for the progression of stem cell based therapies to treat muscular
dystrophy.
1.3. Skeletal muscle regeneration
Adult skeletal muscle is capable of a remarkable degree of
regeneration, suggesting the presence of a stem cell population
either resident within muscle or capable of migrating to
muscle. The major component of adult skeletal muscle is the
myofiber; a giant syncytial cell containing hundreds of
myonuclei within a continuous cytoplasm. Under physiological
conditions the ability of adult muscle to undergo regeneration
is largely attributed to a distinct subpopulation of myogenic
cells, termed satellite cells, located between the basal lamina
and sarcolemma of mature skeletal muscle fibers [47,48].
Despite the fact that satellite cells are multipotent in that they
can give rise to osteogenic, chondrogenic and adipogenic cells
under appropriate conditions [49], they are a distinct lineage of
myogenic stem cells that remain mitotically quiescent under
normal physiological conditions. Upon muscle damage or in a
state of disease, satellite cells activate and proliferate giving
rise to a population of cells that contribute to muscle
regeneration via a process of differentiation and fusion
[50,51]. Satellite cells can be characterized by a panel of cell
surface markers including: M-cadherin [52], c-Met [53],
Syndecan 3 and 4 [54,55], CD-34 [56], and nuclear markers
Pax7 [57], MNF [58], and Myf5 [56]. Patients afflicted with
DMD rapidly exhaust their satellite cell reserves due to
continuous cycles of muscle injury and regeneration [59], and
as such lose their ability to regenerate, resulting in compro-
mised muscle function and degeneration.
2. Applications of typical muscle stem cells
2.1. Transplantation of satellite cell derived myoblasts
Satellite cells are present at low quantities in adult muscle
and account for 2–5% of sublaminar nuclei associated with
myofibers [60]. Due to their scarcity and the difficulties in
isolating pure populations, freshly isolated satellite cells have
been largely neglected as a source for cell therapy. The progeny
of muscle satellite cells, upon culture and expansion in vitro, are
termed primary myoblasts, these cells are highly proliferative
and can be maintained in an undifferentiated state [61,62].
Historically primary myoblasts have been the principal source
of muscle progenitors for cell-based therapies aimed at treating
muscular dystrophy. Myoblast transplantation (MT) involves
the delivery of primary unmodified skeletal myoblasts to
muscle typically via an intramuscular injection. This method is
advantageous in that muscle biopsies are easily conducted on
limb musculature, techniques for genetic modification of
myoblasts are efficient, and large quantities of in vitro expanded
myoblasts are easily achieved.The potential of MT originates from initial experiments
performed in mice which demonstrated the capacity of donor
myogenic cells to regenerate recipient muscle [63–65].
Experiments conducted by Partridge et al. using the immortal
C2C12 mouse myoblast cell line validated the ability of
exogenous myoblasts to induce synthesis of dystrophin in
dystrophin-deficient mdx muscle fibers [66]. Subsequent
experiments confirmed and elaborated upon these results by
using myoblasts from newborn [67] or adult mice [68,69] in
addition to human myoblasts [70,71] as donor cells for
transplant into mdx mice. These experiments demonstrated
the ability to track the transplanted cells in the host through the
use of LacZ staining, or in the case of human myoblast transfer
antibodies specific for human dystrophin. MT was later tried in
non-human primates in order to assess the regenerative capacity
and immune response involved. Primate derived myoblasts
successfully integrated into allogenic hosts when injected 1 mm
apart and in combination with the immunosuppressive FK506
[72–74]. These experiments indicate that primate derived
myoblasts could integrate into regenerating muscle and survive
after 1 year, however none of these experiments provide any
evidence as to whether the transplanted cells provide any
physiological correction of the dystrophic phenotype.
On the basis of research conducted in mice and nonhuman
primates, human clinical trials involving the transplantation of
myoblasts were initiated in the early 1990s [75,76]. Initial trials
involved repetitive intramuscular injections of large quantities
of myoblasts (>106 cells) distributed over multiple sites.
Although reported as successful [76], functional evidence was
elusive and plagued with false positives resulting from revertant
fibers [77], which arise from a second mutation and occur due to
either a somatic deletion or through splicing of further exons in
the dystrophin gene. These events lead to the restoration of the
reading frame allowing for the production of a truncated, yet
partially functional dystrophin molecule [78]. Later clinical
trials involved techniques to distinguish dystrophin-positive
fibers derived from donor DNA from host revertant fibers.
These techniques eliminate confusion concerning the contri-
bution of donor cells to muscle regeneration and allow for
a more confident assessment of physiological benefit post
transplantation.
The majority of past experiments involving myoblast
transfer to treat DMD failed to show substantial physiological
correction of the dystrophic phenotype [79–85]. Although,
recent clinical attempts show improvement in the areas of cell
survival, migration, and evasion of the immune response, these
issues remain at the forefront of myoblast transplantation
[86,87]. Since grafted myoblasts have limited migration,
repeated local injections are required to treat a significant
portion of the myofibers in any given muscle. Considering
DMD patients succumb to heart and diaphragm failure, repeated
injections 1 to 2 mm apart would be required in these muscles to
ensure patient survival, a technique that is currently beyond our
grasp. In addition, transplanted myoblasts do not participate in
long term muscle regeneration making them less than ideal for
the treatment of DMD. In conclusion, while myoblast transfer
provides transient delivery of dystrophin and improves the
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interim solution to ease the suffering of patients with muscular
dystrophy. In order to be considered a viable widespread
treatment option for DMD, myoblasts must contribute to
multiple rounds of regeneration and be conducive to widespread
distribution throughout the musculature.
2.2. Satellite cell transplantation
The ability to directly isolate a pure population of satellite
cells from diaphragm muscle, by using a Pax3-GFP knock-in
mouse [88], was recently accomplished. This Pax3-GFP mouse
incorporates the green fluorescent protein (GFP) under the
control of the Pax3 promoter allowing faithful recapitulation
of Pax3 expression. The use of fluorescent activated cell
sorting (FACS) permits the purification of a GFP positive
population of Pax3+/CD34+/Pax7+ cells. Based on gene
expression, these results suggest the isolation of a predom-
inantly quiescent population of satellite cells. When injected
into dystrophic muscle, this population of cells is capable of
restoring dystrophin expression 3 weeks post-transplantation.
Importantly, the yield of dystrophin expressing muscle
obtained when small numbers of isolated satellite cells were
transplanted into irradiated muscle was significant. Freshly
isolated satellite cells not only restored dystrophin expression
in mdx mice but also formed roughly 17% of the satellite cell
pool expressing both Pax7 and Pax3-GFP; an indication that
donor cells were capable of contributing to the muscle
satellite cell compartment. Moreover, approximately 25 fold
more cells are needed to obtain similar levels of regeneration
from donor cells isolated by enzymatic dissociation of whole
adult muscles, as opposed to grafting Pax3-GFP sorted cells
[62].
However, the full potential of this approach is affected by
several limitations. First, the cultivation of freshly isolated
satellite cells in vitro significantly reduces their in vivo
myogenic potential; therefore, whether or not sufficient
numbers of donor satellite cells can be obtained is a key
issue. The isolation of sufficient quantities of Pax3-GFP
satellite cells is difficult because these cells can only be
isolated from the diaphragm and body trunk muscles but not
from limb muscles. In fact, the current absence of appropriate
cell surface markers to identify a Pax3+/CD34+/Pax7+
population of satellite cells makes this isolation technique
impossible in humans. Given that genetic manipulations
generally require short-term cultivation in vitro, and in vitro
culture decreases the regenerative potential of Pax3-GFP
populations, then genetic correction of autologous sorted
satellite cells does not appear to be a viable option. This is
particularly important from a clinical standpoint since cell
transplantation of autologous genetically corrected satellite
cells to DMD patients is theoretically the ideal approach to
minimize host immune rejection of donor cells. A clinically
relevant approach to using fresh satellite cells would involve
their isolation from the peripheral musculature, based on a panel
of cell surface markers, subsequent culture in vitro under
conditions that promote the maintenance of their stem cell state,followed by gene therapy prior to transplantation. In the
absence of cell surface markers to isolate quiescent satellite
cells from the musculature this alternative is currently not an
option; therefore, research into the identification of a feasible
isolation strategy is of the utmost importance.
2.3. Single muscle fiber
Experiments conducted in the early 1980s involving the
transplant of whole muscle indicated that resident satellite cells
are capable of initiating regeneration [89,90]. While, enzymatic
dissociation and the subsequent transplantation of satellite cells
from myofibers results in marginal muscle regeneration, the
transplantation of satellite cells still associated with a single
muscle fiber (containing as few as seven satellite cells) can
generate in the range of 100 myofibers with thousands of
corresponding myonuclei [91]. Interestingly, the satellite cells
resident upon a transplanted myofiber will contribute to the
host satellite cell compartment and be available for multiple
rounds of regeneration. Transplanted satellite cells appear to
migrate throughout the muscle in which the myofibers were
implanted; however, no direct quantification of the migratory
potential of donor satellite cells exists. The notion that single
muscle fibers will be used to treat muscular dystrophy does
not in itself present a realistic therapeutic approach. Questions
regarding the procurement of donor muscle fibers is
somewhat belied by the large regenerative potential of
individual satellite cells. However, no evidence suggests
donor satellite cells are able to populate neighboring muscles;
indicating that this method of cell transplant would involve
multiple transplantations.
In general the data presented in this section provides
evidence that quiescent satellite cells maintained in their niche
retain a large degree of regenerative potential. Once it is
possible to simulate the satellite cell niche in vitro the real
potential of satellite cells could be harnessed for therapeutic
purposes. Experiments conducted with fresh satellite cells as
well as intact muscle fibers allude to the necessity of
identifying the molecular mechanisms responsible for satellite
cell self renewal and differentiation. The drastic increase in
regenerative potential from either freshly isolated satellite cells
or intact myofibers suggests a link between the maintenance of
the satellite cell niche and the efficiency of muscle
regeneration. Future experiments to identify the components
of the satellite cell niche that are responsible for the activation
or maintenance of satellite cells in a quiescent state will be of
great importance for the validation of satellite cell based
therapies.
3. Applications of atypical muscle stem cells
3.1. Muscle side population cells
Within muscle, in addition to satellite cells, there exists a
population of stem cells that possess myogenic potential,
termed side population (SP) cells. This stem cell population,
isolated by FACS based on its exclusion of the Hoechst 33,342
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from many adult tissues [92]. SP cells isolated from bone
marrow (bmSP) or muscle (mSP) on their own are unable to
undergo myogenic differentiation in vitro, yet upon intramus-
cular transplantation can give rise to both myocytes and satellite
cells [25,93]. The mSP population when isolated from a Pax7−/−
background, where satellite cells are absent, and co-cultured
with myoblasts or forced to express MyoD undergo muscle
specification. These data suggest mSP cells and satellite cells
constitute distinct populations that progress along different
myogenic pathways [57]. Studies directly comparing muscle
regeneration after intravenous injection of bone marrow side
population bmSP and mSP cells indicated a reduced ability of
the mSP fraction to reconstitute the hematopoietic compartment
in lethally irradiated mice; however, both populations regener-
ate muscle to a similar degree [25].
In contrast to satellite cells or primary myoblasts, mSP cells
are able to migrate from the blood stream into muscle, a
desirable feature for widespread distribution of a therapeutic
cell type. Intravenous transplantation of mSP cells typically
yields at most a 1% engraftment rate, however upon delivery
into noninjured, nonirradiated mdx mice via femoral artery
catheterization mSP cells engraftment into muscle at rates
approaching 5–8% in select muscles [94,95]. These results
provide evidence that, under physiological conditions, the mSP
population can provide dystrophin to diseased muscle via
arterial transplantation.
One aspect of mSP transplantation is puzzling, if mSP cells
can take up the satellite cell position, and this is reported in
numerous articles [25,93,95], why do they not appear to
contribute to long term muscle regeneration? Perhaps mSP give
rise to a committed myogenic satellite cell expressing Pax7
rather then a satellite cell with stem cell-like properties? Further
advances in the field of mSP transplantation must address the
following issues: low levels of integration following arterial or
intramuscular transplantation, an inability to partake in long
term regeneration, and achieving physiological improvements
to dystrophic muscle. Prior to these issues being resolved mSP
cells currently do not constitute a viable cell source to treat
DMD.
3.2. Bone marrow cells
Bone marrow transplantation (BMT) or hematopoietic stem
cell transplantation (HSCT) involves the transplantation of
hematopietic stem cell (HSC) in order to produce new blood
cells and repopulate the bone marrow [96]. Evidence of a
population of circulating cells with myogenic potential present
in the bone marrow was identified in the late 1960s. Ferrari et al.
(1998) later confirmed that BM-derived cells can, at very low
levels, undergo myogenic differentiation and participate in
muscle repair after injury [26]. This research presented the idea
of delivering donor cells via the circulation to take part in
skeletal muscle regeneration; a potentially powerful develop-
ment considering the daunting task of injecting donor cells into
individual muscle masses. The following year studies involving
the transplantation of BM-derived cells conducted in the mdxmouse partially restored dystrophin expression [25]. Bone
marrow derived cells persist in the musculature for long periods
of time and maintain their dystrophin expression, however
quantitatively the amount of muscle generated after a BM
transplant does not comprise a therapeutically relevant amount
when only 0.5% of regenerating fibers contain donor cells
[97,98].
A clear mechanism detailing the process by which cells in
the bone marrow contribute to muscle regeneration remains
elusive. Experiments conducted by LaBarge et al. attempted to
elaborate on the process by which bone marrow cells contribute
to muscle regeneration by the transplantation of bone marrow
derived cells (BMDCs) into irradiated SCID mice [99]. BMDCs
appear to contribute following muscle irradiation to the satellite
cell niche and further exercise induced damage led to the
incorporation of BMDCs into multinucleated myofibers at a
frequency approaching 3.5%. These initial experiments have
been elaborated upon using exercise as opposed to muscle
irradiation leading to the conclusion that BMDC can incorpo-
rate into muscle under physiological conditions [100]. Howev-
er, the question remains whether integration of cells from the
bone marrow into muscle is a physiologically relevant process.
Experiments by Camargo et al. and Corbel et al. (2003)
analyzed the ability of bone marrow derived HSCs to participate
in muscle regeneration; and while both studies found HSC
progeny could incorporate into muscle, this ability is more
likely attributed to fusion rather then the existence of a
myogenic HSC [101,102]. Other hematopoietic stem cell
populations exist including the CD45+/Sca-1+ population,
which following muscle injury undergoes a 30 fold expansion
in regenerating muscle and readily undergoes myogenic
differentiation in vitro [103]. These experiments further
concluded that Wnt signaling molecules play a role in
augmenting the myogenic specification of CD45+/Sca1+ cells.
Although, later experiments would lead to the conclusion that
under physiological conditions bone marrow, and the HSCs
contained within, play a minor role in muscle regeneration [104]
this technique in combination with appropriate growth factors
and suitable methods for transplantation may eventually serve
as a method to treat DMD.
Although the major stem cell component of bone marrow is
that of the HSC, and the contribution of bone marrow derived
cells to the physiological process of muscle regeneration is
considered by some to be trivial, the contribution of cells in the
bone marrow may differ significantly between mice and
humans. AC133, a human cell surface marker for the hema-
topoietic/endothelial lineages was recently used to isolate a
population of cells from human blood that can, upon in vitro co-
culture with myogenic cells or exposure to Wnt-producing cells,
undergo a degree of myogenic conversion [105]. This finding
has reopened the debate on a blood born population with
myogenic potential. These AC133+ cells, when co-cultured or
exposed to Wnts, display an mRNA pattern reminiscent of that
found in satellite cells including: M-cadherin, Pax7, CD34 and
Myf5. Whether AC133+ cells constitute a true myogenic
progenitor is difficult to determine considering these cells
do not undergo myogenic differentiation spontaneously when
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limited myogenic conversion and dystrophin expression is
observed upon intra-arterial injection or intramuscular injec-
tion of AC133+ cells. This method offers certain advantages
over other HSC populations including: engraftment of donor
cells under physiological conditions exceeds that shown
previously for bone marrow, HSCs or mSP cells, and
functional tests of injected muscles revealed a substantial
recovery of force after treatment. Considering these qualities
this method to treat DMD warrants further analysis regarding
the process by which the AC133+ population contributes to
myogenic regeneration, the localization of AC133+ cells
within the circulatory system, and the ability to expand ex
vivo these cells prior to transplantation.
3.3. Mesenchymal stem cells
Multipotent mesenchymal stem cells (MSCs), first derived
from bone-forming progenitor cells resident in the bone
marrow, are capable of producing skeletal muscle in addition
to osteoblasts, chondroblasts, and adipocytes [106–108].
Typical methods for MSC isolation involve percoll fractionation
and subsequent culture with varying growth factors [109]. The
debate surrounding the pluripotent nature of MSCs continues;
indeed reports suggest a population of cells co-purified with
MSCs can, in vitro, differentiate into visceral mesoderm,
neuroectoderm and endoderm [110]. These pluripotent stem
cells are termed multipotent adult progenitor cells or MAPCs.
MAPCs appear to reside in the brain, skeletal muscle, and bone
marrow of human and mouse tissues [111]. Being adult derived;
MAPCs avoid many ethical and immunological hurdles
associated with embryonic stem cells facilitating their thera-
peutic application. Continuing research must focus on the
origins of MAPCs and the molecular mechanisms that govern
their development as well as the ability to induce myogenesis
from these cells prior to them being a potential therapeutic
source to treat DMD.
Other MSC populations exist and can be isolated via
enzymatic digestion and serial passaging of cells from adult
human synovial membrane (hSM-MSCs) [112]. These hSM-
MSCs possess multilineage potential in vitro and recapitulate
the temporal gene expression typical of embryonic myogenesis
when directly injected into injured TA muscles of immunosup-
pressed mdx mice [113]. hSM-MSCs can engraft into
regenerating muscle, express dystrophin, and give rise to
putative satellite cells that persist for 6 months after transplan-
tation. However, the gene expression profile of hSM-MSC
derived satellite cells must be clarified considering neither
M-cadherin, Pax7, or CD34 are shown to be expressed in these
cells. A method to resolve this issue would be to conduct single
cell clonal analysis to confirm the ability of hSM-MSC derived
satellite cells to proliferate and give rise to multi-nucleate
myotubes. At this point in time additional research into the
physiological benefits of hSM-MSCs post transplantation,
as well as the confirmation of satellite cell characteristics
are necessary in order to progress therapeutically with this
technique.In addition to the MSC types stated above there exists a
method to convert MSCs to the skeletal muscle lineage [114]
via infection with activated Notch in the presence of various
cytokines. Notch is a transmembrane protein, which upon
binding with its ligands Delta or Jagged, undergoes cleavage to
release an intracellular domain (NICD) in order to effect
downstream signaling. The Notch signaling pathway is
involved in embryonic tissue morphogenesis [115], adult cell
fate selection [116], and has been linked to satellite cell
activation and muscle differentiation, making it a candidate
molecule for the myogenic induction of MSCs [117].
Experiments conducted by Dezawa et al. (2005) demonstrate
the ability to generate skeletal muscle progenitors from human
and rat MSCs. Single cell clonal analysis confirms the ability
of isolated muscle-MSCs (M-MSCs) to form multi-nucleate
myotubes following treatment with the NICD and culture in
low concentrations of horse serum to induce fusion.
Intravenous injection of M-MSCs in immunosuppressed rats,
pretreated with cardiotoxin in the gastrocnemius muscle,
resulted in their incorporation into newly formed myofibers,
and not bone, heart, liver, kidney or undamaged muscle. M-
MSCs localize to the sublaminar portion of myofibers, express
Pax7 and c-Met via immunofluorescence of separate cellular
fields and upon multiple rounds of regeneration contribute to
muscle repair.
Questions remain regarding the contribution of M-MSCs
under physiological conditions to the functional amelioration of
the dystrophic phenotype. Interestingly, M-MSCs express
myogenin (a terminal marker of muscle differentiation) at
high levels along with MyoD, early markers of muscle
formation Six1, and Six4 along with Pax7 a satellite cell
marker. Considering their gene expression profile M-MSCs
appear to be a heterogeneous population of undifferentiated and
partially differentiated myogenic progenitors. Further charac-
terization of M-MSCs and the in vivo derived satellite cells is
required to answer these questions. In addition, the use of Notch
to induce myogenic specification is a unique approach more
commonly associated with the maintenance of quiescent
satellite cells or the prevention of terminal muscle differenti-
ation. This is not to say the use of Notch to promote myogenic
specification is improper, however without a clear molecular
mechanism governing the role of Notch in the myogenic
commitment of MSCs nor a basis for converting MSCs to the
myogenic lineage without over-expressing the NICD this
current route is not practical for the treatment of patients with
DMD. This method offers the ability to derive myogenic cells
that can be easily obtained and expanded from patients,
genetically modified in vitro, and re-introduced via the
circulation all beneficial therapeutic characteristics.
In summary, multiple different types of MSCs can be isolated
and serve as potential cell types for therapy, however in the
absence of a defined group of cell surface markers a
reproducible system to isolate cells with myogenic potential
from MSCs becomes difficult. The reproducible isolation of
pure MSC populations and their downstream differentiation into
the muscle lineage holds tremendous potential for the treatment
of neuromuscular disorders. Given the rapid progress in the
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relevancy may not be far off.
3.4. Muscle Derived Stem Cells (MDSCs)
Muscle derived stem cells (MDSCs) are a distinct population
of stem cells resident in adult skeletal muscle. MDSCs are
thought to reside upstream of satellite cells in the terms of their
potency, and are not restricted to either the myogenic or
mesenchymal lineages [118,119]. Numerous muscle derived
stem cell populations have been shown to contain hematopoi-
etic potential [93,120,121] the most prominent being that
derived via the preplate technique [22]. These MDSCs represent
a heterogeneous population of cells in terms of their high
expression of either Sca1 or CD34. While the physiological
location of MDSCs remains unknown they often express MNF
and the myogenic regulatory factor MyoD and share certain
characteristics with a population of hematopoietic stem cells
expressing CD34 and Sca1 [122]. When injected into limb
muscle or into the circulation of mdx mice MDSCs contribute to
muscle regeneration and express dystrophin [123,124]. In
comparison to transplantations conducted with primary myo-
blasts, MDSCs show a 10 fold increase in dystrophin expression
and incorporate into vessels and surrounding nerves [22].
Although certain characteristics of MDSCs including their
ease of proliferation in vitro, ability to migrate through the
vasculature, and their multipotentiality are amenable to
therapeutic applications, a lack of physiological improvement
to the dystrophic condition coupled with long term self renewal
resulting in their transformation mar the use of MDSCs to treat
DMD [125,126]. In an attempt to determine the physiological
location of MDSCs, some reports claim they originate in the
bone marrow and reside in the musculature [120] while others
claim they are muscle derived [126,127]. Further research into
the origins of MDSCs is required prior to the clinical use of
these cells.
3.5. Vessel associated stem cell populations
Cells with endothelial and myogenic properties exist and can
be isolated at embryonic, fetal [128], and postnatal stages [129]
(3 weeks) of development yet the identification of a bona fide
adult vessel derived stem cell remains elusive. In 1999 De
Angelis et al. discovered a stem cell population resident in the
embryonic dorsal aorta having both endothelial and myogenic
markers [130]. Although, explant cultures of the dorsal aorta do
not initially express any myogenic markers; upon differentiation
in culture they gain both endothelial and myogenic markers
known to be present on adult muscle satellite cells. Surprisingly,
the quantity of satellite cells produced in vitro from the dorsal
aorta is in the range of 50 fold more than that derived from
somitic explants [130]. Dorsal aorta derived myogenic cells can
in vitro fuse with primary myoblasts during differentiation and
when transplanted into TA muscles contribute their nuclei to
muscle regeneration [130].
Further work on vessel associated stem cells isolated from
the dorsal aorta demonstrated their multi-potentiality leading totheir classification as mesangioblasts [131]. Studies conducted
by Sampolesi et al. using immunocompetent α-sarcoglycan null
mice which serve as a model system to study limb-girdle
muscular dystrophy indicated that the intra-arterial injection of
mesangioblasts results in their migration throughout the
vasculature, giving rise to both morphological and functional
correction of the dystrophic phenotype, a quality absent in other
myogenic stem cell populations [132]. This method was further
improved by the treatment of mesangioblasts with either
stromal-derived factor (SDF) 1 or tumor necrosis factor (TNF)
α which resulted in enhanced transmigration in vitro and
migration into dystrophic muscle in vivo [133]. The combina-
tion of pretreatment with TNFα and SDF-1 and the expression
of α-4 integrin lead to remarkable (∼50%) incorporation of
arterially transplanted mesangionblasts into α-sarcoglycan
deficient muscle. Long term survival of pre-treated mesangio-
blasts is observed in muscle masses after 4 months, with α-
sarcoglycan mice expressing ∼60% of the α-sarcoglycan
detected in a wild type mouse. Although these reports are
extremely promising, confirmation of the human equivalent of
mesangioblasts that can be isolated from adult tissue is of great
importance.
Pre-treated mesangioblast can migrate through the vascula-
ture, engraft at therapeutic levels in muscle, persist and
contribute to long term regeneration, and upon genetic
modification of autologous cells do not elicit an immune
response. Due to these qualities mesangioblasts constitute a
potential therapeutic cell type to treat DMD. Prior to their use in
clinical trials effective methods to isolate mesangioblasts from
adult human tissue must be established, information regarding
their long term contribution to muscle function, and the effects
of unwanted penetration into non desired cell types must be
resolved.
Research supporting the vascular origins of myogenic stem
cell populations provides therapeutic potential for the system-
atic delivery of myogenic progenitors. Whether or not these
populations (embryonic, fetal or post natal) of vessel associated
stem cells are unique, or derived from an upstream stem cell
remains to be determined. Considering these cells are associated
with the vasculature it is not a stretch to imagine stem cell
populations with myogenic potential residing in multiple adult
tissues. While the exact characteristics of vessel associated stem
cells remains a mystery their ability to migrate throughout the
vasculature coupled with their myogenic potential make them
an attractive source for use in cell therapy.
4. Embryonic stem cells
Small quantities of skeletal muscle were first derived from
murine embryonic stem (ES) cells nearly 20 years ago [40],
however since then few advances have been made to improve
the efficiency of the process. First reports regarding gene
expression patterns, functional properties, and morphology of
ES derived skeletal muscle parallel observations in vivo
[40,134]. Gene targeting in ES cells is often used to assess
gene function, and as a result numerous ES cell lines with
modifications to genes important in myogenesis exist.
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mouse these ES cell lines were analyzed during in vitro
differentiation to study the molecular mechanisms involved in
embryonic myogenesis [135–139]. Over time limited inhibitors
[140] and activators [141] of skeletal muscle formation from ES
cells were identified along with strategies to harness their
potential for regenerative medicine [142].
One study conducted by Barberi et al. and published in 2005
shows therapeutic potential and involves the derivation of
skeletal muscle by way of hES derived mesenchymal stem cells
[143]. This method offers the ability to derive unlimited
numbers of pure MSCs from hESCs, and their subsequent
differentiation into the skeletal muscle lineage. In order to
obtain skeletal muscle from hES derived MSCs (hESMPCs)
either co-culture or conditioned medium from the murine
myoblast cell line C2C12 or the addition of 5-AzaC as a
demethylating agent is required. Currently these experiments do
not address the ability of hESMPCs to give rise to Pax7 positive
cells nor their ability to contribute to muscle regeneration in
vivo.
ES cells to date have not had a significant impact on the
development of cell-based therapies to treat muscular dystro-
phy. Currently one study exists involving differentiated ES cells
(3 days) co-cultured with dissociated skeletal muscle fibers for 4
days prior to transplantation into mdx muscle [144]. After
2 weeks dystrophin expression was detected in select regions
over and above that which would occur naturally from revertant
fibers. These experiments represent the preliminary steps for the
use of ES cells to treat DMD and currently do not demonstrate
any indication of the long-term regenerative capacity of
transplanted cells. Questions remain as to the mechanism by
which ES cells, co-cultured in the presence of adult skeletal
muscle, contribute to the process of muscle regeneration.Fig. 2. Diversity of myogenic stem cell populations. The identification of various ste
localization within the body. Abbreviations mSP (Muscle Side Population), MDSCCurrently no methods exist to generate large quantities of
skeletal muscle from ES cells and for this reason the ES cell
model system remains better suited as a tool to study embryonic
myogenesis. Potential benefits of using ES cells to treat
muscular dystrophy focus on the isolation of large quantities
of myogenic stem cells, their ease of genetic modification in
vitro, and the ability to derive immune matched cell lineages for
transplant. Although the creation of patient specific hES cell
lines remains mired in controversy, the principle retains a high
degree of feasibility [145] and in the interm progress on the
mechanisms involved in myogenic induction and differentiation
continue.
5. Synergistic methods to improve stem cell based therapies
In this chapter we have presented numerous stem cell types
with varying degrees of myogenic potential. Irrespective of
their source, these stem cell populations share certain hurdles
to overcome prior to their therapeutic use. Survival and the
subsequent migration from the site of injection remains
suboptimal for many of the cell populations outlined
previously and from a clinical standpoint the immune response
generated upon introduction of a foreign cell type, or in the
case of DMD a foreign protein, is a concern. As the
mechanisms surrounding the survival and proliferation of
myogenic cells post transplant are unraveled [146,147] and
appropriate growth factors [148–150] are identified the success
of cell based therapies to treat muscular dystrophy will
improve. Mechanisms involved in the migration of donor
cells to skeletal muscle and the satellite cell niche are still
poorly understood. Although some stem cell types, namely
mesangioblasts, mSP cells, M-MSCs, have the ability to
migrate through the vasculature, most do not. Potential futurem cell populations with myogenic potential along with their known or potential
(Muscle Derived Stem Cell), HSC (Hematopoietic Stem Cell).
280 F.D. Price et al. / Biochimica et Biophysica Acta 1772 (2007) 272–283avenues to increase the migratory ability of stem cell
populations include the identification of cell surface markers
[151] (e.g., L-selectin+ cells) and appropriate growth factors
[152–155]. As is observed in the case of mesangioblasts, pre-
treatment with the growth factors TNFα and SDF-1 led to a
substantial improvement in their migratory abilities.
Cell transplantation often elicits an immune response, and
in addition to immunosuppressive drugs, there exist methods
to overcome immune rejection. One such method involves
the establishment of central immune tolerance through a
process of mixed hematopoietic chimerism [156]. The
mechanism surrounding mixed hematopoietic chimerism is
not fully understood yet the procedure is well established in
animal models and pursued in the clinic [157]. Matching the
genetic background of the various stem cell derived
myogenic precursors with hematopoietic stem cells could
potentially allow the tolerisation of patients to myogenic
transplants.
Irrespective of the stem cell population chosen to treat
muscular dystrophy the above-mentioned characteristics (sur-
vival, localization, and immunogenicity) remain. In order for
the chosen cell type to be successful it must be optimized to deal
with these issues. The identification of suitable growth factors,
appropriate surface markers, and methods to escape immune
detection will be of great importance for the progression of this
field.
6. Conclusions and future perspectives
Stem cell therapy is an attractive method to treat muscular
dystrophy because in theory only a small number of cells,
together with a stimulatory signal for expansion, are required to
elicit a therapeutic effect. In order to achieve clinical relevance
candidate stem cell populations must be easily obtained, upon
isolation remain capable of efficient myogenic conversion, and
when transplanted must integrate into the musculature leading
to the functional correction of the dystrophic phenotype.
Stem cell populations with myogenic potential can be
derived from multiple regions of the body at various stages of
development (Fig. 2). Many questions linger regarding the
mechanisms by which atypical, or non satellite cell derived
precursors, participate in muscle regeneration. A general
consensus in the field identifies satellite cells as the primary,
if not only, physiologically relevant population that contributes
significantly to muscle regeneration. However, because satellite
cells are not currently amenable for distribution throughout the
vasculature they do not constitute a viable option to treat DMD.
A superficial comparison of the atypical myogenic stem cell
populations reveals a common theme whereby a cell often
linked to the circulatory system is able to migrate to
regenerating muscle and contribute in a limited way to this
process. The localization of adult mSP, MDSCs, Mesangio-
blasts, Bone Marrow derived HSCs and HSC populations
expressing the cell surface marker AC133 remains unknown.
The idea that myogenic potential resides in cells associated with
the vasculature is not novel, in fact pericytes which line the
capillaries appear to possess qualities of multipotent mesen-chymal progenitors [158,159]. If indeed pericytes take part in
myogenic regeneration this could explain the widespread
distribution of atypical stem cell populations with myogenic
potential.
In conclusion, upon comparing the prospective stem cell
populations with myogenic potential, the cell type that fulfills
the most criteria for use in the treatment of DMD is the
mesangioblast. Mesangioblasts serve as a paradigm for
widespread distribution, and upon growth factor pre-treatment
are able to correct significantly the dystrophic phenotype.
Perhaps the application of growth factor pre-treatment to other
myogenic stem cell populations may improve their ability to
treat muscular dystrophy, however for now mesangioblasts
serve as a beacon of hope for patients suffering from various
muscular dystrophies.
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